ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
Healthcare
$13.34 +0.42%
+$0.04 today
- Market cap
- $2.96B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
52W Low $7.21High $20.46
Volume 3.62M
Average 7.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$50.40M
FY 2025 · Annual
-57.5% YoYInvesting Cash Flow
-$21.89M
FY 2025 · Annual
Financing Cash Flow
-$44.02M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| Deferred Income Tax | 220.76K | 0 | 0 | (84.28M) | 11.02M |
| Stock-Based Compensation | 3.49M | 5.22M | 6.19M | 13.62M | 20.03M |
| Change in Working Capital | (51.68M) | (18.29M) | (10.12M) | (18.54M) | (139.6M) |
| Accounts Receivables | (15.34M) | 13.07M | (11.92M) | (22.58M) | (108.43M) |
| Inventory | (43.19M) | (38.56M) | (9.63M) | 2.67M | (36.23M) |
| Accounts Payables | 1.36M | 799.98K | 3.84M | 4.15M | 2.33M |
| Other Working Capital | 5.49M | 6.4M | 7.58M | (2.78M) | 2.74M |
| Other Non-Cash Items | 1.75M | 12.35M | 32.64M | 2.16M | 3.92M |
| Operating Cash Flow | (112.37M) | (59.51M) | 8.8M | 118.67M | 50.4M |
| Capital Expenditures | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (22.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (210K) | (349K) | (316K) |
| Investing Cash Flow | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (21.89M) |
| Debt Repayment | (34K) | 51.71M | (23.6M) | (60M) | (3.18M) |
| Common Stock Issued | 121.14M | 64.65M | 0 | 7.49M | 2.98M |
| Common Stock Repurchased | 0 | 0 | (1.42M) | 0 | (31.94M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (62K) | (7.51M) | (13.97M) | (5.8M) | (11.89M) |
| Financing Cash Flow | 121.05M | 108.85M | (38.99M) | (58.3M) | (44.02M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.83M) | 35.43M | (35.17M) | 51.8M | (15.52M) |
| Free Cash Flow | (125.88M) | (73.42M) | 3.82M | 110.1M | 27.82M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$146.9M
+ D&A$8.1M
+ Stock-Based Comp$20.0M
+ Deferred Tax$11.0M
- Working Capital-$139.6M
+ Other Non-Cash$3.9M
= Operating Cash Flow$50.4M
- Capex-$22.6M
= Free Cash Flow$27.8M
Analysis
FY2025 free cash flow is $27.8M. FCF conversion is 18.9% of net income. Operating cash flow was $50.4M, with capex of -$22.6M. The largest bridge item is Working Capital at -$139.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Aug 7, 2026 |
Does ADMA generate free cash flow?
ADMA Biologics, Inc. (ADMA) generated $27.82M of free cash flow in fiscal 2025.
How much operating cash flow does ADMA produce?
Operating cash flow was $50.40M, before capital expenditures of $22.57M.
Continue the stock analysis
Jump to another research area for this company.